A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation
- PMID: 39892392
- PMCID: PMC11925124
- DOI: 10.1016/j.molcel.2025.01.003
A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation
Abstract
Amplification of chromosomal material derived from 12q13-15 is common in human cancer and believed to result in overexpression of multiple collaborating oncogenes. To define the oncogenes involved, we overexpressed genes recurrently amplified in human liposarcoma using a zebrafish model of the disease. We found several genes whose overexpression collaborated with AKT in sarcomagenesis, including the tRNA methyltransferase METTL1. This was surprising, because AKT phosphorylates METTL1 to inactivate its enzymatic activity. Indeed, phosphomimetic S27D or catalytically dead alleles phenocopied the oncogenic activity of wild-type METTL1. We found that METTL1 binds the multi-tRNA synthetase complex, which contains many of the cellular aminoacyl-tRNA synthetases and promotes tRNA aminoacylation, polysome formation, and protein synthesis independent of its methyltransferase activity. METTL1-amplified liposarcomas were hypersensitive to actinomycin D, a clinical inhibitor of ribosome biogenesis. We propose that METTL1 overexpression promotes sarcomagenesis by stimulating tRNA aminoacylation, protein synthesis, and tumor cell growth independent of its methyltransferase activity.
Keywords: AKT; METTL1; aminoacylation; sarcoma; tRNA; translation.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.A. is a consultant for Bayer, AstraZeneca, and Astellas Pharma and receives research funding from Epizyme, EMD Serono, Karyopharm Therapeutics, SpringWorks Therapeutics, Astellas Pharma, Deciphera, and Pharma Mar. J.A.M. is a founder, equity holder, and advisor to Entact Bio, serves on the scientific advisory board (SAB) of 908 Devices, and receives or has received sponsored research funding from Vertex, AstraZeneca, Taiho, Springworks, TUO Therapeutics, and Takeda. J.R.P. is a consultant for ProFound Therapeutics. R.I.G. is a co-founder and advisory board member of Redona Therapeutics, and scientific advisor to Alida Biosciences. A.G. is an advisory board member of Attivare Therapeutics.
Similar articles
-
METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation.Mol Cell. 2021 Aug 19;81(16):3323-3338.e14. doi: 10.1016/j.molcel.2021.06.031. Epub 2021 Aug 4. Mol Cell. 2021. PMID: 34352207 Free PMC article.
-
N7-methylguanosine tRNA modification promotes gastric cancer progression by activating SDHAF4-dependent mitochondrial oxidative phosphorylation.Cancer Lett. 2025 Apr 10;615:217566. doi: 10.1016/j.canlet.2025.217566. Epub 2025 Feb 16. Cancer Lett. 2025. PMID: 39965707
-
METTL1/WDR4-mediated tRNA m7G modification and mRNA translation control promote oncogenesis and doxorubicin resistance.Oncogene. 2023 Jun;42(23):1900-1912. doi: 10.1038/s41388-023-02695-6. Epub 2023 Apr 25. Oncogene. 2023. PMID: 37185458
-
Processivity of translation in the eukaryote cell: role of aminoacyl-tRNA synthetases.FEBS Lett. 2010 Jan 21;584(2):443-7. doi: 10.1016/j.febslet.2009.11.027. FEBS Lett. 2010. PMID: 19914240 Review.
-
tRNA synthetase: tRNA aminoacylation and beyond.Wiley Interdiscip Rev RNA. 2014 Jul-Aug;5(4):461-80. doi: 10.1002/wrna.1224. Epub 2014 Apr 4. Wiley Interdiscip Rev RNA. 2014. PMID: 24706556 Free PMC article. Review.
Cited by
-
METTL1-driven nucleotide metabolism reprograms the immune microenvironment in hepatocellular carcinoma: a multi-omics approach for prognostic biomarker discovery.Front Immunol. 2025 Apr 22;16:1582203. doi: 10.3389/fimmu.2025.1582203. eCollection 2025. Front Immunol. 2025. PMID: 40330476 Free PMC article.
-
METTL1 in human cancers: recognition of their functions, mechanisms and therapeutic value.Oncol Rev. 2025 Jul 30;19:1637372. doi: 10.3389/or.2025.1637372. eCollection 2025. Oncol Rev. 2025. PMID: 40809384 Free PMC article. Review.
-
METTL9 sustains vertebrate neural development primarily via non-catalytic functions.Nat Commun. 2025 Aug 1;16(1):7051. doi: 10.1038/s41467-025-62414-5. Nat Commun. 2025. PMID: 40745158 Free PMC article.
References
-
- Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244, 217–221. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials